Tony Arulanandam
CEO Synaptimmune Therapeutics
Seminars
Wednesday 10th September 2025
Conditionally active 41BB Costimulatory CD19 x CD20 T Cell engager designed for deeper and durable responses and minimal cytokine release for Autoimmune Diseases
2:15 pm
- Costimulation built in CD19 x CD20 T Cell Engager (TCE) to achieve CAR-T like potency, immune reset, and efficacy for Autoimmune diseases
- Conditional Activation of TCE only in the presence of antigen engagement overcomes cytokine release syndrome associated with conventional TCEs
- Shows increased potency and efficacy in the humanized SLE mouse model compared to benchmark TCE BlinatumomabTM and other CD19 and CD20 TCE’s in development for Autoimmune Diseases
